Massachusetts Financial Services Co. MA lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,160,027 shares of the biopharmaceutical company's stock after buying an additional 139,491 shares during the period. Massachusetts Financial Services Co. MA owned approximately 1.06% of Amicus Therapeutics worth $33,749,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of FOLD. William Blair Investment Management LLC boosted its position in Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company's stock valued at $128,993,000 after buying an additional 1,477,084 shares during the last quarter. Fiera Capital Corp grew its stake in Amicus Therapeutics by 1.1% during the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company's stock valued at $52,382,000 after purchasing an additional 58,113 shares in the last quarter. Victory Capital Management Inc. grew its stake in Amicus Therapeutics by 17.9% during the 2nd quarter. Victory Capital Management Inc. now owns 2,273,959 shares of the biopharmaceutical company's stock valued at $22,558,000 after purchasing an additional 345,117 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Amicus Therapeutics by 141.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 2,037,896 shares of the biopharmaceutical company's stock worth $21,765,000 after purchasing an additional 1,192,489 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Amicus Therapeutics by 1,758.9% in the 2nd quarter. Millennium Management LLC now owns 1,894,176 shares of the biopharmaceutical company's stock valued at $18,790,000 after purchasing an additional 1,792,277 shares in the last quarter.
Amicus Therapeutics Stock Up 1.5 %
Shares of Amicus Therapeutics stock traded up $0.15 during midday trading on Tuesday, reaching $9.87. 1,534,997 shares of the company's stock traded hands, compared to its average volume of 2,709,086. The company has a market cap of $2.95 billion, a price-to-earnings ratio of -29.15 and a beta of 0.68. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57. The company's 50 day simple moving average is $10.80 and its 200 day simple moving average is $10.59. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.
Wall Street Analysts Forecast Growth
A number of research firms have commented on FOLD. JPMorgan Chase & Co. increased their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, November 12th. Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a "buy" rating and a $18.00 target price on the stock. Guggenheim lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $17.63.
Get Our Latest Research Report on FOLD
Insiders Place Their Bets
In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company's stock, valued at approximately $9,398,532.40. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders sold 30,401 shares of company stock worth $352,038. 2.20% of the stock is currently owned by company insiders.
About Amicus Therapeutics
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Read More
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
